CC Chemours Co

NYSE chemours.com


$ 14.02 $ 0.17 (1.22 %)    

Friday, 24-Oct-2025 18:19:12 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 14.05
$ 14.12
$ 14.00 x 151
$ 14.33 x 40
$ 13.93 - $ 14.23
$ 9.08 - $ 21.71
1,875,108
na
2.1B
$ 1.71
nm
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-18-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 10-27-2023 09-30-2023 10-Q
9 07-28-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 02-10-2023 12-31-2022 10-K
12 10-26-2022 09-30-2022 10-Q
13 07-29-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-11-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 05-05-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-06-2020 03-31-2020 10-Q
23 02-14-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-15-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 02-25-2016 12-31-2015 10-K
40 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mizuho-maintains-outperform-on-chemours-lowers-price-target-to-18

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $18.

 ubs-maintains-buy-on-chemours-raises-price-target-to-21

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $17 to $21.

 mizuho-maintains-outperform-on-chemours-raises-price-target-to-19

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $16 to $19.

 truist-securities-maintains-buy-on-chemours-raises-price-target-to-21

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $21.

 agri-science-giant-corteva-eyes-breakup-to-shield-seed-unit-from-future-risks-report

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...

 chemours-chair-dawn-farrell-resigns-effective-sept-2-to-lead-canadian-governments-new-major-projects-office

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors (the "Board") of The Chemours Company (the "Compa...

 dupont-divests-aramids-business-in-18-billion-deal-to-sharpen-portfolio

DuPont agreed to sell its Aramids business, including Kevlar and Nomex brands, to Arclin for $1.8B. Deal aligns with DuPont'...

 chemours-sees-q3-sales-1518b-1550b-vs-1557b-est

Chemours (NYSE:CC) sees Q3 sales of $1.518 billion-$1.550 billion vs $1.557 billion analyst estimate.

 chemours-sees-fy2025-sales-5900b-6000b-vs-5901b-est

Chemours (NYSE:CC) sees FY2025 sales of $5.900 billion-$6.000 billion vs $5.901 billion analyst estimate.

 chemours-q2-adj-eps-058-beats-048-estimate-sales-1615b-beat-1571b-estimate

Chemours (NYSE:CC) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.48 by 20.83 p...

Core News & Articles

Settlement payments will total $875 million over a 25-year period beginning within 30 days of the Judicial Consent Order ("...

 mizuho-maintains-outperform-on-chemours-raises-price-target-to-16

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $13 to $16.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION